Purpose: There is little information about the efficacy of intravitreal vascular endothelial growth factor (VEGF) inhibition in vitrectomized eyes. This study aimed to evaluate the efficacy of anti-VEGF (ranibizumab) on diabetic macular oedema in previously vitrectomized eyes. Methods: A nationwide retrospective review of medical records from 2010 to 2013. Results: We identified 33 previously vitrectomized eyes in 28 patients treated with ranibizumab injections for diabetic macular oedema. Median follow-up was 323 days (interquartile range 72-1404 days). Baseline mean visual acuity was 0.57 logMAR (95% CI 0.13-1.01) before injections. After an average of 4.7 injections (range 1-15), mean visual acuity remained stable at 0.54 logMAR (95% CI 0.13-0.95) with a mean improvement of 0.03 (p = 0. 45, 95% CI À0.12 to 0.06). In 12 eyes (36%), visual acuity improved 0.1 logMAR or more, in 12 eyes (36%), vision was unchanged (gain or loss of 0-0.05 logMAR), and in nine eyes (27%), vision decreased 0.1 logMAR or more. Mean central foveal thickness (CFT) on optical coherence tomography (OCT) scan was 412 lm (95% CI 390-434 lm) before injections. After injections, the mean CFT decreased to 352 lm (95% CI 334-370 lm). The mean reduction in CFT was 14% (95% CI 4-24%, p = 0.01). Sixteen eyes (48.5%) became devoid of oedema on the last OCT scan. Despite the significant reduction in CFT, the visual acuity remained unchanged. Conclusion: Intravitreal ranibizumab can be effective in previously vitrectomized eyes with diabetic macular oedema. However, the response is variable and should be carefully monitored.
Introduction
Diabetic macular oedema (DMO) is a frequent cause of visual loss in patients with diabetes mellitus. If left untreated, more than 50% of patients lose more than two Early Treatment Diabetic Retinopathy Study (ETDRS) lines of visual acuity within 2 years (Ferris & Patz 1984) . Until recently, the standard therapy for DMO was focal or grid laser photocoagulation, which stabilized vision (Mitchell et al. 2011) . However, randomized clinical trials (Nguyen et al. 2009; Brown et al. 2013 ) have reported a visual improvement of 5.2-12.5 ETDRS letters after 6-24 months when diabetic macular oedema is treated with intravitreal 0.5 mg of ranibizumab (Lucentis Ò , Novartis, Basel, Switzerland). A very recent multicentre randomized clinical trial has reported a mean gain in visual acuity letter score from baseline to the 5-year visit of 7.2 letters in the prompt laser group compared with 9.8 letters in the deferred laser group when using ranibizumab for the treatment of DMO (Elman et al. 2015) . One-year data from a very recent DRCR Network publication have studied the relative efficacy and safety of aflibercept, bevacizumab and ranibizumab in the treatment of DMO. The mean visual letter score improved by 13.3 with aflibercept, 9.7 with bevacizumab and 11.2 when using ranibizumab (DRCR Network and Wells 2015) . Reports from daily clinical practice have also been favourable (Brynskov et al. 2013) , and ranibizumab was recommended as first line of treatment of DMO with visual impairment and foveal centre involvement during our study period (Bandello et al. 2012) .
Even though treatment of diabetic retinopathy has improved dramatically, pars plana vitrectomy is still utilized when there is unresolving vitreous haemorrhage, retinal traction (Mandelcorn et al. 1976; Ostri et al. 2014) and DMO with significant vitreomacular traction (Laidlaw 2008) .
In vitrectomized eyes, drugs are believed to be more rapidly distributed throughout the eye than in an eye with an intact vitreous gel. This usually leads to a substantial decrease of the drug's half-life (Stef ansson 2009). It is therefore to be expected that the clearance of ranibizumab is increased after vitrectomy and maybe even more so in eyes that have undergone both vitrectomy and lensectomy. The effect of this phenomenon on intraocular pharmacotherapy is not easily predicted. In theory, molecular mediators of diabetic macular oedema, most notably vascular endothelial growth factor (VEGF), are likely to be 'washed away' from the retina faster than when the vitreous is in place, leading to a potential diminishing effect of anti-VEGF under such circumstances. Conversely, vitrectomy may promote the delivery of oxygen to the retina and wash away VEGF, which may also reduce macular oedema and the stimulus for neovascularization in the posterior pole (Stef ansson 2009). The net effect and clinical relevance of these potentially counteracting mechanisms of vitrectomy and intravitreal anti-VEGF therapy is unknown. To investigate the clinical effect of anti-VEGF after vitrectomy in the individual patient, we performed a retrospective study of eyes treated with ranibizumab for DMO after vitrectomy in the daily clinic.
Materials and Methods
We conducted a retrospective nationwide review of medical records of all identifiable previously vitrectomized patients with DMO who received intravitreal injections with ranibizumab from 2010 to 2013. Codes for anti-VEGF treatment and vitrectomy are continuously registered in a national registry using unique CPRnumbers for each patient. Data were included from centralized eye centres from three of five administrative regions in Denmark, where such treatment was available under the public universal-coverage healthcare system. The other two centres had not yet treated vitrectomized eyes with anti-VEGF for DMO. We did not have any exclusion criteria. All patients were included.
Ranibizumab was administered intravitreally following the recommendations by the European Medicines Agency and was usually initiated with a series of three monthly intravitreal injections of 0.5 mg ranibizumab followed by a flexible retreatment regimens where 1-3 injections with intervals of 4 weeks or longer were given as needed (Brynskov et al. 2013) . Two patients received only 1 or 2 initial injections. None of the centres gave injections with a shorter time span than 4 weeks or used higher doses of ranibizumab. Cases without evidence of reduced macular thickness on optical coherence tomography (OCT) after injection and lack of improvement of best-corrected visual acuity (BCVA) were generally observed without treatment. At all control visits, the following was assessed: best-corrected visual acuity by Snellen or ETDRS chart, spectral domain OCT scanning (Heidelberg Engineering, Heidelberg, Germany; Topcon 3D OCT-2000, 3-D OCT-1000, Topcon, Tokyo, Japan; Zeiss Stratus, Carl Zeiss Meditec, Jena, Germany) including mean central foveal thickness (CFT) as measured by the proprietary software of each manufacturer. The same OCT machine was used for each patient's follow-up. Changes in CFT were registered and are given as percent change compared to preinjection.
The study was performed in accordance with the criteria of the Declaration of Helsinki.
Statistical analysis was performed using SAS 9.4 (SAS institute Inc, Cary, USA). Baseline characteristic data were not normally distributed and reported as medians and interquartile range (IQR). Optical coherence tomography (OCT) changes were logarithmically transformed to achieve normal distribution, and visual acuity was transformed to logMAR values before analysis. Differences between numerical values before and after injections were tested with Student's paired t-test. The relationship between lens status and best-corrected visual acuity outcome was tested using a one-way ANOVA model. Proportions were compared with a v 2 -test. The level of statistical significance was set to p < 0.05.
Results
We identified 33 previously vitrectomized eyes in 28 patients treated with ranibizumab injections for DMO. None was omitted. Baseline data are presented in Table 1 . The median duration of diabetes was 28 years . The majority of patients (n = 23 eyes, 70%) had type 2 diabetes. Median age was 63 years (IQR 25-80), and there was a slight majority of male patients (55%).
Patient history
The vitrectomies were performed with large variation in both timing and operating procedure. Two patients received the first anti-VEGF injection at the end of the vitrectomy procedure, while one patient had the first injection 4172 days after the vitrectomy. None of the patients had received intraocular silicone oil. Peeling of the internal limiting membrane was performed in one patient. In all cases, the reason for vitrectomy was vitreous haemorrhage Only seven eyes remained phakic throughout the follow-up period. The other eyes had cataract surgery carried out either prior to (n = 20) or during the course of the intravitreal injections (n = 6). None of the patients was suspected having pseudophakic oedema.
The majority of eyes had received macular photocoagulation prior to the intravitreal injections (n = 27). No eyes received macular laser treatment after initiating injections with ranibizumab. Panretinal photocoagulation had been performed in all eyes but two prior to the injections with anti-VEGF.
The time period of follow-up was defined as the time from the first injection with anti-VEGF until the last visit of control. Median follow-up was 323 days (IQR 72-1404 days).
Treatment observations
Overall treatment observations and numbers of injections are presented in Table 2 .
Mean visual acuity was 0.57 log-MAR (95% CI 0.13-1.01) before injections. After an average of 4.7 injections (range 1-15), mean visual acuity remained stable at 0.54 logMAR (95% CI 0.13-0.95) with a mean improvement of 0.03 (p = 0. 45, 95% CI À0.12 to 0.06). Twelve eyes (36%) gained 0.1 logMAR or more, in 12 eyes (36%), vision was unchanged (gain or loss of 0-0.05 logMAR), and in nine eyes (27%), vision decreased 0.1 logMAR or more. Factors associated with a gain of visual acuity and reduction in CFT were tested in a multiple regression model. We tested for age, sex, baseline CFT, baseline visual acuity, diabetes type, diabetes duration and cataract surgery. Gain of vision was independent of age and type of diabetes (p = 0.49). Longer duration of diabetes (p < 0.001) and cataract surgery (p < 0.001) were associated with a better outcome in visual acuity in multiple regression analysis. None of the factors tested was associated with reduction in CFT.
Mean central foveal thickness (CFT) was 412 lm (95% CI 390-434 lm) prior to commencing ranibizumab injections. After an average of 4.7 injections (range 1-15), CFT had decreased by 14% (95% CI 4-24%, p = 0.01). Mean CFT after injections was 352 lm (95% CI 334-370 lm). Sixteen eyes (48.5%) became devoid of oedema with no signs of intra-or subretinal fluid on the last optical coherence tomography scan. Despite the significant reduction in CFT, the visual acuity remained unchanged.
Among the 17 eyes that had macular oedema at the final OCT, six eyes (35%) had slight parafoveal or epiretinal fibrosis. Among the 16 eyes having no sign of oedema, only two eyes (13%) had parafoveal or epiretinal fibrosis, but there was no statistical difference between these proportions (p = 0.13, v 2 -test).
Safety
No case of endophthalmitis was observed in relation to the 160 injections.
One patient with ischaemic heart disease died due to an acute myocardial infarction following a lower limb amputation 54 days after the last ranibizumab injection.
Discussion
This study found a significant reduction in macular oedema in previously vitrectomized patients who received intravitreal ranibizumab injections for DMO. We found that 16 of 33 eyes (48.5%) were dry without oedema on the last recorded OCT after a regular PRN treatment regimen. These results are encouraging.
Many of the patients with unresolved macular oedema at the final OCT had concurrent parafoveal atrophy and/or epiretinal or parafoveal fibrosis, which could suggest that the best results may be achieved among patients without fibrosis. However, our study could not prove this statistically, most likely due to the relatively low number of patients. The same phenomenon was found in a large cohort study of patients with diabetes undergoing phacoemulsification. The probability of gaining vision after cataract surgery was smaller if the patient had received focal laser treatment in the macula for clinically significant macular oedema prior to the cataract surgery (Ostri et al. 2011) .
Many of the eyes in this study had received prior macular laser treatment (n = 27), which could increase the amount of parafoveal and epiretinal fibrosis and weaken the effect of ranibizumab, underlining the importance of paying attention to the vitreomacular interface before and during treatment (Yoon et al. 2014) . Six eyes of a total of eight eyes with epiretinal fibrosis on the final OCT scan had received central laser prior to the intravitreal injections.
The ocular transport and elimination of molecules are increased after vitrectomy unless the vitreous is replaced with a viscous substance such as silicone oil (Stef ansson 2009). Studies with rabbit models that have quantitatively compared ocular elimination of drugs in vitrectomized eyes versus non-vitrectomized eyes have all found an increase in clearance; by a factor between 1.5 and 2.4 for triamcinolone acetonide (Schindler et al. 1982; Chin et al. 2005) , by the factor 2.2 for Table 2 . Overall treatment results after treatment with intravitreal ranibizumab injections for diabetic macular oedema in 33 previously vitrectomized eyes. ciprofloxacin (Pearson et al. 1993 ) in aphakic eyes and by the factor 6.5 for amphotericin (Doft et al. 1985) in aphakic eyes. Another study where paracentesis in five human eyes were performed at different intervals after intravitreal triamcinolone acetonide injection found a half-life of 18.6 days in non-vitrectomized eyes and 3.2 days in vitrectomized eyes with a considerable intrasubject variation (Beer et al. 2003) .
Ranibizumab is a humanized monoclonal antibody of 48kD and a potent inhibitor of all known isoforms of VEGF-A. Vascular endothelial growth factor (VEGF) is released by retinal cells in response to hypoxia and plays a pivotal role in the formation of macular oedema stimulating angiogenesis and capillary leakage (Ferrara et al. 2006) . Ranibizumab is injected into the vitreous cavity from where it is cleared in two pathways of the eye: an anterior route through the trabecular meshwork and a posterior route across the retina to the choroid circulation (Maurice & Michima 1984; Gaudreault et al. 2005) .
In rabbit models, the half-lives of bevacizumab and ranibizumab were recently found to be reduced with a factor 1.8 and 1.3, respectively, in eyes undergoing pars plana vitrectomy (Christoforidis et al. 2013) . Another study reporting on the clinical effect of bevacizumab on macular oedema, a 140-kDa full-length monoclonal VEGF antibody, did not find any clinical improvement in 11 vitrectomized eyes (Yanyali et al. 2007) . Results from rabbit experiments indicate that the clearance of ranibizumab was faster than for bevacizumab and that the intravitreal retention was significantly reduced for both agents after vitrectomy and lensectomy (Beer et al. 2003) . Hence, more frequent dosing regimen could be considered in vitrectomized eyes. However, ranibizumab may prolong its own clearance due to its effect on vessel permeability. This may explain data from rabbit experiments using ranibizumab on vitrectomized eyes versus non-vitrectomized eyes (Ahn et al. 2014) finding no statistically significant difference of ranibizumab concentration in vitreous, aqueous humour or retina between the two groups, suggesting avoid using different dosing regimens of ranibizumab in vitrectomized eyes. A regimen of more frequent dosing in the treatment of these patients was not used in either of the three centres involved. For that reason, we cannot test the present set of data to see whether patients on a treatment regimen with a more frequent dosing fared better.
A recent study by the Diabetic Retinopathy Clinical Research Network (DRCRnet) comparing 25 previously vitrectomized eyes with 335 eyes without a history of vitrectomy both treated with ranibizumab did not identify substantial differences in visual acuity, CFT or volume outcomes on OCT at each annual visit through 3 years, although improvement on OCT appeared slower in vitrectomized eyes during the first year (Bressler et al. 2015) .
We did not plan to compare treatment results of vitrectomized eyes with a control group. A control group could have strengthened this study. Some in our study group have previously published data from a real-life setting of non-vitrectomized eyes with DMO receiving ranibizumab (Brynskov et al. 2013) . The DRCRnet study included a large control group (n = 335), but did not find any substantial difference except of a slower improvement on OCT in vitrectomized eyes during the first year of treatment ranibizumab (Bressler et al. 2015) .
Another limitation of this study is the relatively small number of vitrectomized eyes. This is also the case in the DRCRnet study (n = 25) mentioned above (Bressler et al. 2015) . Our study is looking at 33 previously vitrectomized eyes, which is higher than in the DRCRnet study.
Other limitations are very heterogeneous follow-up period and differences in methods across the centres (different OCT scanning machines). But the same OCT machine was used for each patient's follow-up, and only changes in CFT were registered and are given as percent change compared to preinjection.
In conclusion, in this nationwide retrospective survey, we found that ranibizumab resolved the macular oedema in 48.5% of the patients. Despite the significant reduction in CFT, visual acuity remained unchanged. Visual improvement was mostly seen in eyes undergoing cataract surgery and was due to the cataract operation itself. Intravitreal ranibizumab may be considered for use in vitrectomized eyes, but the patients should be carefully monitored to identify eyes that improve and may eventually benefit from retreatment, as opposed to eyes that have no detectable effects of treatment. The role of anti-VEGF compared to other treatment options; that is, ozurdex remains to be investigated.
